Rilpivirine

證據等級: L5

預測適應症: 5 個

Rilpivirine: From HIV-1 Infection to Congenital Human Immunodeficiency Virus

One-Sentence Summary

Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) originally approved globally for treating HIV-1 infection in adults. The TxGNN model predicts it may be effective for congenital human immunodeficiency virus (perinatally acquired HIV-1 in children and adolescents), backed by 10+ Phase 3 clinical trials and 5 publications at the highest evidence level (L1). Among the 5 TxGNN predictions in this pack, congenital HIV is the strongest human clinical opportunity; AIDS-related complex (rank 4) represents a secondary L2-level finding also warranting attention.

Quick Overview

Item	Content
Original Indication	HIV-1 infection in adults (globally approved; not registered in Taiwan)
Predicted New Indication	Congenital Human Immunodeficiency Virus
TxGNN Prediction Score	99.56%
Evidence Level	L1
Taiwan Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Rilpivirine acts as an NNRTI by binding non-competitively to HIV-1 reverse transcriptase (RT), locking the enzyme in an inactive conformation and halting viral DNA synthesis. Unlike first-generation NNRTIs (nevirapine, efavirenz), its flexible diarylpyrimidine scaffold can adopt different binding orientations, preserving activity against many common NNRTI-resistance mutations. It is marketed in the US and Europe as Edurant® (standalone tablet) and as part of fixed-dose combinations including Complera®, Odefsey®, Juluca® (DTG/RPV), and Cabenuva® (CAB LA/RPV LA injectable). Detailed MOA documentation is pending DrugBank DB08864 retrieval.

Congenital (perinatally transmitted) HIV-1 refers to infection acquired from mother to child in utero, intrapartum, or via breastfeeding. The HIV-1 virus in perinatally infected children targets the same reverse transcriptase as in adults — Rilpivirine’s mechanism applies directly and without modification. There is therefore no pharmacological barrier to extending this indication; the critical adaptations involve weight-based dosing, developmental pharmacokinetics, and formulation choice (daily oral tablet vs. long-acting injectable) rather than any new mechanism of action.

The long-acting injectable combination cabotegravir + rilpivirine (CAB+RPV LA), approved in the US and EU, is particularly well-suited to this population. Poor daily oral adherence is a recognized challenge in pediatric HIV management, and CAB+RPV LA’s every-4- or every-8-week injection schedule directly addresses this gap. Multiple large Phase 3 RCTs — including ATLAS-2M (n=1,049), FLAIR (n=631), and ATLAS (n=618) — establish non-inferiority versus standard triple oral therapy. A dedicated pediatric Phase 1/2 study (NCT03497676, n=168) confirms appropriate drug exposure in children and adolescents, and a 2025 systematic review (PMID 41225339) addresses safety in the perinatal context.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03299049	Phase 3	Active	1,049	ATLAS-2M: CAB LA + RPV LA Q8W vs. Q4W in virologically suppressed HIV-1 adults — non-inferiority confirmed; largest trial in the Rilpivirine LA program
NCT02938520	Phase 3	Active	631	FLAIR: Long-acting IM CAB + RPV vs. INI single-tablet regimen after oral induction in ART-naïve HIV-1 adults; evaluates switch to LA maintenance
NCT02951052	Phase 3	Active	618	ATLAS: Switch from INI/NNRTI/PI-based triple therapy to CAB LA + RPV LA in virologically suppressed HIV-1 adults
NCT02422797	Phase 3	Completed	518	DTG + RPV two-drug switch: virologically suppressed HIV-1 adults maintain suppression after switching from triple regimen to two-drug oral regimen
NCT02429791	Phase 3	Completed	510	Parallel non-inferiority RCT confirming DTG + RPV two-drug maintenance vs. triple therapy; serves as independent replication of NCT02422797
NCT06694805	Phase 3	Recruiting	332	CROWN: CAB LA + RPV LA superiority trial vs. standard of care in viremic HIV-1 patients with incomplete suppression on oral ART; most current design
NCT05917509	Phase 3	Active	171	Hybrid study: oral DTG/3TC induction followed by participant-determined optional switch to CAB + RPV LA Q2M in ART-naïve HIV-1 adults
NCT03639311	Phase 2	Completed	97	POLAR: Long-term durability of CAB LA + RPV LA Q2M through Week 312 in rollover participants from the LATTE study
NCT03497676	Phase 1/2	Completed	168	Dedicated pediatric study: safety, PK, tolerability, and dose-finding for oral CAB and CAB LA + RPV LA in virologically suppressed HIV-infected children and adolescents
NCT01266902	Phase 3	Completed	482	Long-term continued-access study of TMC278 (Rilpivirine) + 2 NRTIs in HIV-1 patients completing earlier Phase 2b/3 trials; provides long-term safety dataset

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41225339	2025	Systematic Review / Meta-analysis	BMC Infectious Diseases	Safety of cabotegravir (+ rilpivirine) LA in pregnancy: supports use of long-acting regimen with appropriate monitoring; notes limited long-term infant outcome data as remaining gap
36411596	2023	Observational Cohort	HIV Medicine	Pregnancy outcomes and PK washout data in women living with HIV exposed to CAB + RPV LA; documents pharmacokinetic changes during gestation and their implications for vertical transmission risk
38864586	2024	Cohort Study	AIDS (London)	US cohort: first-trimester exposure to newer antiretrovirals including Rilpivirine and congenital anomaly rates; establishes safety baseline for RPV use in pregnancy
38703388	2024	Case Report	Clinical Infectious Diseases	Bimonthly CAB/RPV LA throughout pregnancy — RPV concentrations 70–75% lower than in non-pregnant individuals; no virologic failure or vertical transmission; enhanced monitoring recommended
41268510	2025	Case Report	Case Reports in Infectious Diseases	CAB/RPV LA Q2M maintained throughout a complete pregnancy in a perinatally infected woman; viral suppression sustained and no neonatal adverse outcomes reported

Taiwan Market Information

Rilpivirine is currently not registered in Taiwan (0 product licenses on record in the Taiwan FDA database). No product authorization entries are available.

For context: Rilpivirine holds regulatory approvals in the United States (Edurant®, Complera®, Odefsey®, Juluca®, Cabenuva®) and the European Union for HIV-1 treatment in adults, with pediatric labeling extensions available for select formulations. Pursuing a Taiwan import license or full NDA filing is a prerequisite before any domestic clinical prescribing or research protocol can proceed.

Safety Considerations

Please refer to the complete package insert for full safety information (Taiwan FDA package insert data not available in this pack).

Key safety considerations from published pharmacological and clinical data:

Viral load threshold: Not recommended for patients with baseline HIV-1 RNA > 100,000 copies/mL — confirmed higher virologic failure rate in this subgroup across Phase 3 trials
Food requirement: Must be administered with a full meal (≥ 400 kcal); fasting conditions reduce bioavailability by approximately 40%, leading to subtherapeutic exposure
Pregnancy pharmacokinetics: RPV plasma concentrations decrease 30–75% during pregnancy due to expanded volume of distribution and accelerated renal/hepatic clearance — dose review and plasma-level monitoring are required in pregnant patients
QTc prolongation: Reported at supratherapeutic concentrations — exercise caution when co-administering with other QT-prolonging medications; baseline and periodic ECG monitoring may be warranted

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Rilpivirine’s NNRTI mechanism directly targets the same HIV-1 reverse transcriptase present in congenitally infected children and adolescents, and multiple completed Phase 3 RCTs — including ATLAS-2M (n=1,049), FLAIR (n=631), and two parallel DTG+RPV switch trials totaling over 1,000 subjects — provide L1-level evidence for Rilpivirine-containing regimens. The long-acting injectable formulation (CAB+RPV LA) directly addresses the pediatric adherence challenge, and a 2025 systematic review confirms an acceptable safety profile in the perinatal context.

To proceed, the following is needed:

Regulatory access: File for Taiwan import license or full product registration (Edurant®, Juluca®, or Cabenuva®) via TFDA; no domestic prescribing or research protocol is possible until resolved
Package insert review: Retrieve full TFDA/global package insert to complete warnings, contraindications, and drug interaction assessment (Data Gap DG001)
MOA documentation: Query DrugBank DB08864 to formally document mechanism of action (Data Gap DG002)
Pediatric dosing verification: Confirm weight-based dosing protocols for children under 12 years and under 35 kg; review FDA/EMA pediatric labeling for age-appropriate formulations
Pregnancy PK monitoring plan: RPV plasma concentrations decline 30–75% during pregnancy — design a protocol for baseline, second-trimester, and third-trimester plasma-level monitoring with defined thresholds for dose adjustment
National guideline alignment: Map Rilpivirine use against Taiwan CDC vertical transmission prevention programs and national HIV treatment guidelines to identify integration pathway
Secondary indication pathway: Evaluate AIDS-related complex (rank 4, L2, NCT01792570 Phase 3 RCT, n=37) as a concurrent repurposing candidate — note the key limitation that Rilpivirine is contraindicated in ARC patients with high viral burden (> 100,000 copies/mL)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.